Morgan Stanley Rapid Micro Biosystems, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Rapid Micro Biosystems, Inc. stock. As of the latest transaction made, Morgan Stanley holds 10,108 shares of RPID stock, worth $10,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,108

Previous 10,108 -0.0%

Holding current value

$10,916

Previous $6,000 33.33%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 16, 2024	SELL	$0.9 - $1.1 $482 - $589	-536 Reduced 5.04%	10,108 $9,000
Q1 2024 May 15, 2024	SELL	$0.9 - $1.1 $482 - $589	-536 Reduced 5.04%	10,108 $9,000
Q4 2023 Aug 16, 2024	BUY	$0.74 - $1.17 $396 - $627	536 Added 5.3%	10,644 $7,000
Q3 2023 Nov 15, 2023	BUY	$0.89 - $1.18 $388 - $514	436 Added 4.27%	10,644 $11,000
Q1 2023 May 15, 2023	SELL	$1.06 - $1.5 $3,885 - $5,499	-3,666 Reduced 26.42%	10,208 $13,000
Q4 2022 Feb 14, 2023	SELL	$1.13 - $3.5 $7,818 - $24,216	-6,919 Reduced 33.28%	13,874 $15,000
Q3 2022 Nov 14, 2022	SELL	$2.95 - $4.66 $41,400 - $65,398	-14,034 Reduced 40.3%	20,793 $67,000
Q2 2022 Oct 27, 2022	BUY	$2.49 - $6.76 $24,638 - $66,890	9,895 Added 39.69%	34,827 $151,000
Q2 2022 Aug 15, 2022	BUY	$2.49 - $6.76 $24,638 - $66,890	9,895 Added 39.69%	34,827 $151,000
Q1 2022 Oct 27, 2022	SELL	$5.76 - $10.83 $56,995 - $107,162	-9,895 Reduced 28.41%	24,932 $169,000
Q1 2022 May 13, 2022	BUY	$5.76 - $10.83 $95,592 - $179,734	16,596 Added 199.09%	24,932 $169,000
Q4 2021 Feb 14, 2022	BUY	$9.41 - $22.19 $73,972 - $174,435	7,861 Added 1654.95%	8,336 $89,000
Q3 2021 Nov 15, 2021	BUY	$17.88 - $24.8 $8,493 - $11,780	475 New	475 $9,000

Others Institutions Holding RPID

# of Institutions

Shares Held

17.7M

Call Options Held

Put Options Held

View Full List

About RAPID MICRO BIOSYSTEMS, INC.

Ticker RPID
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 36,389,100
Market Cap $39.3M
Description
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumab...

More about RPID

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account